Trial record 31 of 435 for:    hepatitis b | Open Studies

Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by University of California, Los Angeles
Sponsor:
Collaborator:
University of California, Irvine
Information provided by (Responsible Party):
Daniel Furst, University of California, Los Angeles
ClinicalTrials.gov Identifier:
NCT02053727
First received: November 6, 2013
Last updated: August 15, 2014
Last verified: August 2014
  Purpose

The purpose of this study is to investigate whether the combination of abatacept along with entecavir (the study drugs) is safe and effective in treating symptoms related to rheumatoid arthritis (RA).

Abatacept, given in an intravenous (IV - injected into a vein) as well as subcutaneous form, is approved by the FDA for the treatment of RA. In this research, abatacept will be given by injection. A subcutaneous injection is an injection given under the skin.

Entecavir, to be taken by mouth, is approved by the FDA for the treatment of hepatitis B.

The study is divided into the following time periods:

Screening Phase: Up to 4 weeks Randomized Double-blind Phase: 24 weeks Open-label Extension Phase: 24 weeksFollow-up Phase: a phone call after Week 48

Each phase contains one or more study visits.


Condition Intervention
Rheumatoid Arthritis
Chronic Hepatitis B
Drug: Abatacept
Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Pilot Study to Evaluate Subcutaneous Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background- a Pilot, Double-blind, Placebo-controlled, Randomized, Controlled Trial.

Resource links provided by NLM:


Further study details as provided by University of California, Los Angeles:

Primary Outcome Measures:
  • Number of Participants with Serious Adverse Events [ Time Frame: Every 4 weeks from Week 4 to Week 48 ] [ Designated as safety issue: Yes ]
    Adverse events will be assessed at timepoints specified in the protocol.

  • Number of Subjects with Hepatitis B Reactivation [ Time Frame: Every 4 Weeks from Week 4 to Week 48 ] [ Designated as safety issue: No ]
    Blood test for Hepatitis B Virus (HBV) DNA will be used.


Secondary Outcome Measures:
  • DAS28-ESR-4 Unit [ Time Frame: Screening, Weeks 4, 8, 12, 24, 36, and 48 ] [ Designated as safety issue: No ]
  • CDAI Unit [ Time Frame: Screening, Weeks 4,8,12,24,36,48 ] [ Designated as safety issue: No ]
  • TJC Count [ Time Frame: Screening, Weeks 4,8,12,24,36,48 ] [ Designated as safety issue: No ]
  • SJC Count [ Time Frame: Screening, Weeks 4,8,12,24,36,48 ] [ Designated as safety issue: No ]
  • Patient Global (Visual Analogue Scale) [ Time Frame: Screening, Weeks 4,8,12,24,36,48 ] [ Designated as safety issue: No ]
  • MD Global (Visual Analogue Scale) [ Time Frame: Screening, Weeks 4,8,12,24,36,48 ] [ Designated as safety issue: No ]
  • Pain (measured on a 5 point Likert scale) [ Time Frame: Screening, Weeks 4,8,12,24,36,48 ] [ Designated as safety issue: No ]
  • Global Assessment of Disease Activity (as measured on a 5 point Likert scale) [ Time Frame: Screening, Weeks 4,8,12,24,36,48 ] [ Designated as safety issue: No ]
  • HAQ-DI Units [ Time Frame: Screening, Weeks 4,8,12,24,36,48 ] [ Designated as safety issue: No ]
  • Fatigue (as assessed by FACIT-Fatigue Unit) [ Time Frame: Screening, Weeks 4,8,12,24,36,48 ] [ Designated as safety issue: No ]
  • Sleep as assessed by Medical Outcomes Study Sleep Instrument Unit [ Time Frame: Screening, Weeks 4,8,12,24,36,48 ] [ Designated as safety issue: No ]
  • ACR 20/50/70 Percentage [ Time Frame: Screening, Weeks 4,8,12,24,36,48 ] [ Designated as safety issue: No ]

Estimated Enrollment: 20
Study Start Date: July 2014
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Abatacept Arm
This arm of study subjects will receive 125 mg subcutaneous abatacept during the 24 week double blind period.
Drug: Abatacept
Abatacept Injection, 125 mg/Syringe (125 mg/mL), is a sterile solution for SC administration, which contains approximately 126 mg abatacept.
Other Name: Orencia
Placebo Comparator: Placebo Arm
This arm of study patients will receive matching placebo injections during the 24 week double blind period.
Drug: Placebo

Detailed Description:

Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder affecting 1% of the world's population. If not adequately controlled, it may lead to disability in up to 30% of patients within the first three years of disease onset [1] and can be associated with premature death. Recent research has suggested that the first event in the pathogenesis of RA is an antigen dependent activation of T-cells in an immunogenetically susceptible host. T-cells require two signals for activation, one involving the trimolecular complex (class II Major Histocompatibility Complex (MHC), antigen, T-cell receptor), and the other being co-stimulation of the CD28 (Cluster of Differentiation 28) molecule on T-cells by the B7 molecules (CD80 and CD86) on antigen presenting cells.

Hepatitis B virus (HBV) can cause chronic disease in 5% of immunocompetent adults and has a prevalence of over 350 million worldwide. It is a leading cause of chronic hepatitis, cirrhosis and hepatocellular cancer and accounts for one million deaths annually. In patients with chronic hepatitis B and RA, treatment options are limited. Traditional disease modifying anti-rheumatic drugs (DMARDs) are associated with hepatotoxicity and are contraindicated in chronic hepatitis. A recent retrospective analysis suggests that successful use of anti-tumor necrosis factor alpha (anti-TNF) agents may be possible in these patients but the authors do warn that these patients should be closely monitored and that fatal reactivation of hepatitis B is possible. Treatment with rituximab, a chimeric monoclonal antibody against B-cell protein CD20, is another option; however, the use of this medication in RA patients with chronic hepatitis B may also cause reactivation.

When RA patients with chronic hepatitis B were started on a Tumor Necrosis Factor (TNF) inhibitor or methotrexate (MTX), 2 of 5 HBsAg+ patients reactivated their hepatitis B, indicating a possible high rate of activation in these patients when not on hepatitis B treatment. Reactivation in this and another study occurred after 9-19 months of antirheumatic therapy. In RA patients with chronic Hepatitis B, entecavir appears to be effective at preventing reactivation.

There are no studies on the safety of abatacept in patients with RA and HBV. Adequate T-cell function is important to help cure or contain HBV infection. Our site has conducted a retrospective study that shows preliminary safety of abatacept in patients with RA and chronic Hepatitis B on antiviral therapy. The purpose of this study is to assess the safety and efficacy of abatacept in RA patients with chronic Hepatitis B in a pilot study in a randomized, controlled fashion.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Diagnosis of RA.
  2. Baseline CDAI >10 with TJC (Tender Joint Count) > 4 and SJC (Swollen Joint Count) > 2.
  3. Chronic Hepatitis B as defined by a history of patients with a HBsAg positive for at least 6 months with undetectable HBV DNA; or a history of patients with negative HBsAg and positive HBcAb or HBsAb, with undetectable HBV DNA.
  4. No evidence of hepatocellular carcinoma (HCC) based upon alpha-fetoprotein (AFP) ≤20 ng/mL at screening,) negative liver imaging as shown by ultrasound, computerized tomography or magnetic resonance imaging within 24 weeks of screening. Participants with AFP >20 ng/mL must be evaluated clinically with additional imaging and shown not to have HCC on CT or MRI before they can be enrolled.
  5. Oral corticosteroids (≤ 10 mg/day of prednisone or equivalent) and NSAIDs (Non-Steroidal Anti-inflammatory Drugs) are permitted if the patient is on a stable dose regimen for ≥ 2 weeks prior to and including at baseline.
  6. Men and women, >= 18 years of age.

Exclusion Criteria:

  1. Women who are pregnant or breastfeeding. Sexually active fertile men not using effective birth control if their partners are WOCBP (Women of Child Bearing Potential).
  2. Target Disease Exceptions

    a) Rheumatic autoimmune disease other than RA; fibromyalgia or keratoconjunctivitis/xerostomia are allowed, as long as these will not confound the CLINICAL EFFICACY OUTCOMES.

  3. Medical History and Concurrent Diseases

    1. Subjects who are impaired, incapacitated, or incapable of completing study-related assessments.
    2. Subjects who underwent previous MCP (metacarpophalangeal) arthroplasty, have such a procedure scheduled, or anticipate the need for such a procedure during the study.
    3. Major surgery (including joint surgery) within 8 weeks prior to screening
    4. Subjects with active vasculitis of a major organ system, with the exception of rheumatoid nodules or minor rheumatoid vasculitis lesions of the skin
    5. Subjects with current uncontrolled symptoms of severe, progressive, or uncontrolled renal, hepatic hematologic, gastrointestinal, pulmonary, cardiac, neurologic, or cerebral disease, including Cirrhosis with Child-Pugh Class >=2 or COPD (chronic obstructive pulmonary disease) with FEV1 (forced expiratory volume in 1 second) /FVC (forced vital capacity) < 0.6
    6. Female subjects who have had a recent breast cancer screening that is suspicious for malignancy and where the diagnosis is not excluded.

    h) Subjects who currently abuse drugs or alcohol. i) Subjects with evidence of active or latent bacterial or viral infections at the time of potential enrollment, including HIV.

    j) Subjects with herpes zoster or cytomegalovirus (CMV) that resolved less than 2 months before the informed consent document was signed.

    k) Subjects who have received any live vaccines within 3 months of the anticipated first dose of study medication.

    l) Subjects with any serious bacterial infection within the last 3 months, unless treated and resolved with antibiotics, or any chronic bacterial infection.

    m) Subjects at risk for tuberculosis (TB) or not treated for latent TB is tested positive.

    n) Subjects who are positive for hepatitis C antibody if the presence of hepatitis C virus was also shown with polymerase chain reaction or recombinant immunoblot assay.

    o) Subjects who have abnormal laboratory values

  4. Prohibited Treatments and/or Therapies

    1. Subjects who have at any time received treatment with any investigational drug within 28 days (or less than 5 terminal half-lives of elimination) of the Day 1 dose.
    2. Any concomitant biologic DMARD, such as anakinra.
    3. Previous treatment with cell-depleting therapies, including investigational agents, including but not limited to CAMPATH, anti-CD4 (cluster of differentiation 4), anti-CD5, anti-CD3, and anti-CD19.
    4. Anti-CD20 treatment within the last 6 months (OK to include if they were dosed > 6 months ago).
    5. Treatment with methotrexate, hydroxychloroquine, cyclosporine A, azathioprine, mycophenolate mofetil, within <= 4 weeks prior to baseline.
    6. Treatment with etanercept within 2 weeks, infliximab/certolizumab/golimumab/adalimumab with <=8 weeks, anakinra within <=1 week prior to baseline.
    7. Previous abatacept use.
    8. Treatment with sulfasalazine within < 4 weeks prior to baseline
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02053727

Contacts
Contact: Bal-lan Yen 310-206-4112 byen@mednet.ucla.edu
Contact: Gabriel Valdivia 310-794-9504 gvaldivia@mednet.ucla.edu

Locations
United States, California
Division of Rheumatology, UCLA David Geffen School of Medicine Recruiting
Los Angeles, California, United States, 90095
Principal Investigator: Daniel E Furst, M.D.         
Sponsors and Collaborators
Daniel Furst
University of California, Irvine
Investigators
Principal Investigator: Daniel E Furst, M.D. University of California, Los Angeles
  More Information

No publications provided

Responsible Party: Daniel Furst, Carl M Pearson Professor of Rheumatology, University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT02053727     History of Changes
Other Study ID Numbers: IM101329, 13-001279
Study First Received: November 6, 2013
Last Updated: August 15, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by University of California, Los Angeles:
Rheumatoid Arthritis
Hepatitis B
Abatacept
Orencia
entecavir

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis B
Hepatitis B, Chronic
Hepatitis, Chronic
Hepatitis, Viral, Human
Arthritis
Arthritis, Rheumatoid
Autoimmune Diseases
Connective Tissue Diseases
Digestive System Diseases
DNA Virus Infections
Enterovirus Infections
Hepadnaviridae Infections
Immune System Diseases
Joint Diseases
Liver Diseases
Musculoskeletal Diseases
Picornaviridae Infections
Rheumatic Diseases
RNA Virus Infections
Virus Diseases
Abatacept
Entecavir
Anti-Infective Agents
Antirheumatic Agents
Antiviral Agents
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 22, 2014